UNSPSC 51373464: Guaifenesin/hydrocodone/phenindamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373464 Guaifenesin/hydrocodone/phenindamine is a Commodity code that in recent state and local solicitations maps to broader pharmaceutical procurement — specifically naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers to government health and social-service facilities. The code's nominal name does not align with the actual scope of recent opportunities being solicited; state and local buyers are using this code tag for purchase of life-safety and general pharmaceutical inventories rather than the specific branded formulation the code nominally describes. Issuing bodies include county health departments (Seminole County, Florida) and multistate cooperative purchasing alliances administering on behalf of state and local participating members, including Oregon and multiple Minnesota jurisdictions.

Recent activity centers on Florida and the upper Midwest. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building and a two-year initial term with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026; the RFP weighted price competitiveness at 75 percent and required vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC) and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.